Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Elaine Lam

Concepts (314)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Renal Cell
37
2026
229
6.970
Why?
Kidney Neoplasms
40
2026
417
6.490
Why?
Prostatic Neoplasms
13
2023
972
2.800
Why?
Neoplasms, Germ Cell and Embryonal
3
2023
76
1.410
Why?
Antineoplastic Agents
15
2024
2218
1.270
Why?
Prostate-Specific Antigen
4
2023
162
1.130
Why?
Antibodies, Monoclonal, Humanized
12
2025
992
1.100
Why?
Protein Kinase Inhibitors
12
2026
982
1.010
Why?
Antineoplastic Combined Chemotherapy Protocols
15
2025
1996
0.980
Why?
Testicular Neoplasms
3
2023
108
0.900
Why?
Neoplasms, Unknown Primary
1
2025
20
0.880
Why?
Neoplasms
10
2023
2944
0.880
Why?
Antineoplastic Agents, Immunological
2
2025
200
0.830
Why?
Carcinoma, Transitional Cell
4
2025
70
0.780
Why?
Seminoma
2
2021
20
0.770
Why?
Carcinoma, Medullary
2
2013
16
0.700
Why?
Aged
37
2026
26251
0.670
Why?
Retroperitoneal Neoplasms
1
2021
27
0.660
Why?
Urinary Bladder Neoplasms
4
2025
257
0.650
Why?
Male
60
2026
73014
0.640
Why?
Pyridines
6
2026
606
0.630
Why?
Pneumocystis carinii
1
2020
12
0.620
Why?
Teratoma
1
2021
121
0.620
Why?
Carcinoma, Squamous Cell
1
2025
627
0.620
Why?
Spinal Cord Compression
1
2020
24
0.610
Why?
Trimethoprim, Sulfamethoxazole Drug Combination
1
2020
43
0.610
Why?
Pneumonia, Pneumocystis
1
2020
34
0.610
Why?
Euterpe
1
2018
4
0.570
Why?
Humans
87
2026
145625
0.570
Why?
TWEAK Receptor
1
2017
6
0.530
Why?
Middle Aged
39
2026
36359
0.530
Why?
Prednisone
3
2020
229
0.530
Why?
Pyrazoles
3
2022
516
0.510
Why?
Anilides
5
2023
82
0.510
Why?
Abiraterone Acetate
1
2017
15
0.500
Why?
Sulfonamides
3
2015
592
0.500
Why?
Biomarkers, Tumor
6
2025
1334
0.490
Why?
Adrenal Cortex Hormones
1
2020
483
0.490
Why?
Plant Extracts
1
2018
191
0.490
Why?
Aged, 80 and over
17
2025
8351
0.470
Why?
Neoplasm Metastasis
9
2020
693
0.450
Why?
Antineoplastic Agents, Hormonal
2
2015
196
0.450
Why?
Neoplasm Recurrence, Local
3
2023
1156
0.440
Why?
Carcinoma, Papillary
1
2015
83
0.430
Why?
Brain Neoplasms
2
2021
1324
0.430
Why?
Paclitaxel
3
2022
258
0.410
Why?
Everolimus
2
2025
112
0.410
Why?
Patient Reported Outcome Measures
4
2025
502
0.410
Why?
Interleukin-2
2
2014
434
0.410
Why?
Prostatic Neoplasms, Castration-Resistant
3
2022
54
0.400
Why?
Neoplasms, Complex and Mixed
1
2013
7
0.400
Why?
Antibodies, Monoclonal
2
2017
1511
0.380
Why?
Urologic Neoplasms
2
2025
31
0.370
Why?
Treatment Outcome
17
2025
11744
0.350
Why?
Nephrectomy
4
2024
169
0.350
Why?
Retrospective Studies
18
2024
17291
0.350
Why?
Epothilones
1
2011
2
0.350
Why?
Angiomyolipoma
1
2011
21
0.340
Why?
Androgen Antagonists
3
2020
91
0.340
Why?
Carcinoma, Non-Small-Cell Lung
3
2025
1194
0.340
Why?
Deoxycytidine
2
2010
219
0.330
Why?
Multicenter Studies as Topic
1
2012
413
0.320
Why?
Benzenesulfonates
1
2010
23
0.310
Why?
Suramin
1
2010
8
0.310
Why?
Adult
27
2025
40821
0.310
Why?
Lung Neoplasms
4
2025
2674
0.310
Why?
Maximum Tolerated Dose
6
2022
216
0.290
Why?
Radiosurgery
3
2019
398
0.280
Why?
Female
35
2026
79080
0.280
Why?
Immunotherapy
5
2024
669
0.270
Why?
Indenes
2
2025
6
0.270
Why?
Fluorouracil
1
2008
231
0.260
Why?
Disease Progression
3
2021
2857
0.260
Why?
Bone Neoplasms
2
2023
271
0.260
Why?
Quinazolines
1
2008
267
0.250
Why?
Chemotherapy, Adjuvant
3
2013
429
0.240
Why?
Neoplasm Staging
7
2017
1486
0.240
Why?
Practice Guidelines as Topic
4
2024
1581
0.240
Why?
Platinum
2
2024
48
0.240
Why?
Drug Administration Schedule
3
2021
782
0.230
Why?
Proto-Oncogene Proteins c-kit
1
2026
73
0.230
Why?
Thyroid Neoplasms
1
2010
380
0.230
Why?
Sulfones
2
2017
127
0.220
Why?
B7-H1 Antigen
2
2025
245
0.220
Why?
Microsatellite Instability
1
2025
57
0.220
Why?
Prognosis
5
2023
4331
0.220
Why?
Phenylurea Compounds
4
2016
122
0.220
Why?
Benzoxazoles
2
2022
20
0.200
Why?
Melanoma
2
2025
764
0.200
Why?
Ipilimumab
2
2021
44
0.200
Why?
Taste
1
2026
237
0.200
Why?
Taxoids
2
2017
115
0.200
Why?
Taste Buds
1
2026
214
0.190
Why?
Multiple Sclerosis
2
2019
434
0.190
Why?
Bevacizumab
2
2020
167
0.180
Why?
Kaplan-Meier Estimate
5
2024
959
0.180
Why?
Pyrimidines
3
2022
530
0.170
Why?
Quantitative Trait Loci
1
2024
388
0.170
Why?
Mastectomy
1
2023
188
0.170
Why?
Remission, Spontaneous
1
2021
39
0.170
Why?
Administration, Oral
4
2024
867
0.160
Why?
Biliary Tract Neoplasms
1
2021
30
0.160
Why?
Celecoxib
2
2012
42
0.160
Why?
Neoplasm, Residual
1
2021
143
0.160
Why?
Bariatric Surgery
1
2024
248
0.160
Why?
Carboplatin
1
2021
168
0.160
Why?
Phosphatidylinositol 3-Kinases
1
2022
384
0.160
Why?
Syndrome
1
2021
377
0.160
Why?
Proto-Oncogene Proteins c-akt
1
2022
438
0.160
Why?
Combined Modality Therapy
4
2019
1269
0.160
Why?
Quality of Life
2
2025
3187
0.150
Why?
Genomics
1
2025
851
0.150
Why?
Azepines
1
2020
104
0.150
Why?
Cancer Care Facilities
1
2020
48
0.150
Why?
Antiemetics
1
2020
51
0.150
Why?
Thrombosis
1
2023
397
0.150
Why?
Homologous Recombination
1
2019
37
0.150
Why?
Fatal Outcome
1
2020
302
0.150
Why?
TOR Serine-Threonine Kinases
1
2022
454
0.150
Why?
Morpholines
1
2020
130
0.140
Why?
MAP Kinase Kinase Kinases
1
2019
70
0.140
Why?
Streptococcus
1
2019
26
0.140
Why?
Pharyngitis
1
2019
28
0.140
Why?
Disease-Free Survival
4
2016
777
0.140
Why?
Fruit and Vegetable Juices
1
2018
23
0.140
Why?
Drug Hypersensitivity
1
2020
93
0.140
Why?
Anti-Bacterial Agents
2
2020
1935
0.140
Why?
Diagnosis, Computer-Assisted
1
2019
91
0.140
Why?
Feedback
1
2019
180
0.140
Why?
Mutation
2
2025
4082
0.140
Why?
Indans
1
2017
12
0.130
Why?
Neoplastic Cells, Circulating
2
2016
81
0.130
Why?
Cost-Benefit Analysis
1
2021
632
0.130
Why?
Interferon beta-1b
1
2017
2
0.130
Why?
Pancreatic Neoplasms
1
2026
944
0.130
Why?
Proton Therapy
1
2017
16
0.130
Why?
Niacinamide
3
2016
103
0.120
Why?
Liver Neoplasms
1
2023
774
0.120
Why?
Erythrocytes, Abnormal
1
2016
14
0.120
Why?
Genome-Wide Association Study
1
2024
1526
0.120
Why?
Multiple Sclerosis, Relapsing-Remitting
1
2017
66
0.120
Why?
Dose-Response Relationship, Drug
3
2022
2018
0.120
Why?
Hematologic Diseases
1
2016
66
0.120
Why?
Polymorphism, Single Nucleotide
1
2024
2228
0.120
Why?
DNA Damage
1
2019
437
0.120
Why?
Streptococcal Infections
1
2019
179
0.120
Why?
Cell Line, Tumor
3
2020
3538
0.120
Why?
Oncolytic Virotherapy
1
2015
13
0.120
Why?
Neoadjuvant Therapy
2
2023
474
0.120
Why?
Problem Solving
1
2017
154
0.120
Why?
Indazoles
2
2015
86
0.120
Why?
Mammalian orthoreovirus 3
1
2015
38
0.110
Why?
Autoimmune Diseases
1
2020
466
0.110
Why?
Angiopoietin-1
1
2015
12
0.110
Why?
Angiopoietin-2
1
2015
15
0.110
Why?
Pyrroles
1
2016
221
0.110
Why?
Genetic Predisposition to Disease
1
2024
2455
0.110
Why?
Fatigue
2
2022
362
0.110
Why?
Receptor, IGF Type 1
1
2015
64
0.110
Why?
Imidazoles
2
2015
244
0.110
Why?
Kidney Glomerulus
1
2015
129
0.110
Why?
Radiation Tolerance
1
2015
101
0.110
Why?
Proto-Oncogene Proteins p21(ras)
1
2015
250
0.110
Why?
Nanoparticles
1
2021
521
0.100
Why?
Soft Tissue Neoplasms
1
2015
133
0.100
Why?
Severity of Illness Index
2
2019
2910
0.100
Why?
Magnetic Resonance Imaging
2
2021
3917
0.100
Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
109
0.100
Why?
Prefrontal Cortex
1
2017
338
0.100
Why?
Prostatectomy
1
2013
93
0.100
Why?
Patient Satisfaction
1
2017
698
0.090
Why?
Glycine
1
2014
184
0.090
Why?
Indoles
1
2016
509
0.090
Why?
Cohort Studies
5
2021
6045
0.090
Why?
Recombinant Fusion Proteins
1
2015
662
0.090
Why?
Glomerular Filtration Rate
1
2015
743
0.090
Why?
Quinolines
1
2013
191
0.090
Why?
Tubulin Modulators
1
2011
10
0.090
Why?
Emotions
1
2017
555
0.090
Why?
Metabolic Clearance Rate
1
2011
115
0.080
Why?
Algorithms
1
2019
1843
0.080
Why?
Arthralgia
1
2011
61
0.080
Why?
Area Under Curve
1
2011
333
0.080
Why?
Clinical Trials as Topic
1
2015
1062
0.080
Why?
Peripheral Nervous System Diseases
1
2011
133
0.080
Why?
Diarrhea
1
2011
190
0.080
Why?
Mechanistic Target of Rapamycin Complex 1
2
2022
138
0.080
Why?
Breast Neoplasms
1
2023
2411
0.080
Why?
Molecular Structure
1
2011
483
0.080
Why?
Proto-Oncogene Proteins c-ret
1
2010
41
0.080
Why?
Biopsy
1
2013
1073
0.080
Why?
Survival Rate
3
2020
2078
0.080
Why?
Nomograms
1
2010
59
0.070
Why?
Tomography, X-Ray Computed
3
2022
2766
0.070
Why?
Decision Making
1
2017
987
0.070
Why?
Immunohistochemistry
1
2013
1709
0.070
Why?
Radiotherapy, Adjuvant
1
2010
222
0.070
Why?
Drug Synergism
1
2010
353
0.070
Why?
Capecitabine
1
2008
56
0.070
Why?
Infusions, Intravenous
1
2010
429
0.070
Why?
Adenine
2
2022
338
0.070
Why?
Positron-Emission Tomography
1
2010
342
0.070
Why?
Proteinuria
1
2008
103
0.070
Why?
Hypertension, Pregnancy-Induced
1
2008
69
0.060
Why?
Dysgeusia
1
2026
5
0.060
Why?
Follow-Up Studies
3
2020
5397
0.060
Why?
Young Adult
4
2024
14240
0.060
Why?
Creatinine
1
2008
511
0.060
Why?
Risk
1
2008
917
0.060
Why?
Optical Illusions
1
2005
2
0.050
Why?
Urothelium
1
2025
33
0.050
Why?
Risk Factors
2
2020
10840
0.050
Why?
Von Hippel-Lindau Tumor Suppressor Protein
1
2024
19
0.050
Why?
Cell Lineage
1
2026
375
0.050
Why?
Cytoreduction Surgical Procedures
1
2024
69
0.050
Why?
Prospective Studies
3
2021
8087
0.050
Why?
Mastectomy, Segmental
1
2023
107
0.050
Why?
Adjuvants, Immunologic
1
2024
243
0.050
Why?
RNA Interference
1
2024
470
0.050
Why?
Disease Management
2
2017
649
0.040
Why?
Cardiovascular Diseases
1
2014
2218
0.040
Why?
RNA, Small Interfering
1
2024
630
0.040
Why?
Cisplatin
1
2023
346
0.040
Why?
Nephritis, Interstitial
1
2020
11
0.040
Why?
International Agencies
1
2020
30
0.040
Why?
Aurora Kinase A
1
2020
57
0.040
Why?
Drug Evaluation
1
2020
78
0.040
Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
62
0.040
Why?
Lymphocytes
1
2022
379
0.040
Why?
Nausea
1
2020
111
0.040
Why?
Analysis of Variance
2
2017
1293
0.040
Why?
Hong Kong
1
2019
7
0.040
Why?
Vomiting
1
2020
131
0.040
Why?
Time Factors
1
2010
7079
0.040
Why?
Lymphatic Metastasis
1
2020
335
0.040
Why?
Sex Factors
1
2025
2101
0.040
Why?
Hospitals
1
2023
730
0.040
Why?
Mice, Knockout
1
2026
3121
0.040
Why?
Medical Oncology
1
2022
344
0.040
Why?
DNA-Binding Proteins
1
2026
1467
0.030
Why?
Cell Differentiation
1
2026
1979
0.030
Why?
Central Nervous System
1
2020
278
0.030
Why?
Transcription Factors
1
2026
1728
0.030
Why?
Retreatment
1
2017
79
0.030
Why?
Genetic Testing
1
2020
491
0.030
Why?
Databases, Factual
1
2023
1481
0.030
Why?
Drug Therapy, Combination
1
2020
1034
0.030
Why?
Receptor Protein-Tyrosine Kinases
1
2019
226
0.030
Why?
United States
2
2017
16041
0.030
Why?
National Cancer Institute (U.S.)
1
2017
55
0.030
Why?
Xenograft Model Antitumor Assays
1
2020
928
0.030
Why?
Erythrocyte Indices
1
2016
33
0.030
Why?
Anti-Inflammatory Agents
1
2020
473
0.030
Why?
Academic Medical Centers
1
2020
560
0.030
Why?
Antimicrobial Stewardship
1
2019
136
0.030
Why?
Drug-Related Side Effects and Adverse Reactions
1
2019
266
0.030
Why?
Case-Control Studies
1
2024
3633
0.030
Why?
Neutrophils
1
2022
1132
0.030
Why?
Clinical Decision-Making
1
2019
364
0.030
Why?
Mice
2
2026
18266
0.030
Why?
Acute Disease
1
2019
1033
0.030
Why?
Thoracic Neoplasms
1
2015
40
0.030
Why?
Abdominal Neoplasms
1
2015
48
0.030
Why?
Tosyl Compounds
1
2015
17
0.030
Why?
Antibodies, Neoplasm
1
2015
34
0.030
Why?
Kidney Function Tests
1
2015
154
0.030
Why?
Reaction Time
1
2017
434
0.030
Why?
Angiogenesis Inhibitors
1
2016
238
0.030
Why?
Craniocerebral Trauma
1
2017
173
0.030
Why?
Neoplasm Grading
1
2015
313
0.030
Why?
Organ Size
1
2015
463
0.030
Why?
Radiotherapy
1
2015
209
0.030
Why?
Postoperative Period
1
2015
344
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
2015
150
0.030
Why?
Drug Resistance, Neoplasm
1
2020
889
0.030
Why?
Demography
1
2015
274
0.030
Why?
Radiotherapy, Intensity-Modulated
1
2015
143
0.030
Why?
STAT5 Transcription Factor
1
2014
50
0.030
Why?
Animals
3
2026
38030
0.030
Why?
Nitriles
1
2015
211
0.020
Why?
Recurrence
1
2017
1125
0.020
Why?
Drug Interactions
1
2015
403
0.020
Why?
Gonadotropin-Releasing Hormone
1
2015
215
0.020
Why?
Medication Adherence
1
2017
535
0.020
Why?
ErbB Receptors
1
2015
636
0.020
Why?
Cell Survival
1
2015
1102
0.020
Why?
Longitudinal Studies
1
2020
3005
0.020
Why?
Proportional Hazards Models
1
2015
1318
0.020
Why?
Neuropsychological Tests
1
2017
1136
0.020
Why?
Double-Blind Method
1
2016
2064
0.020
Why?
T-Lymphocytes, Regulatory
1
2014
411
0.020
Why?
Molecular Targeted Therapy
1
2014
446
0.020
Why?
Proto-Oncogene Proteins
1
2014
615
0.020
Why?
Enzyme Inhibitors
1
2014
820
0.020
Why?
Biomarkers
1
2022
4329
0.020
Why?
Logistic Models
1
2015
2112
0.020
Why?
Cell Cycle Proteins
1
2014
629
0.020
Why?
Reagent Strips
1
2008
8
0.020
Why?
Primary Health Care
1
2019
1768
0.020
Why?
Urinalysis
1
2008
82
0.020
Why?
Albuminuria
1
2008
190
0.020
Why?
Diagnostic Tests, Routine
1
2008
108
0.020
Why?
Vision, Monocular
1
2005
4
0.010
Why?
Psychophysics
1
2005
15
0.010
Why?
Eye Enucleation
1
2005
16
0.010
Why?
Vision, Binocular
1
2005
47
0.010
Why?
Orientation
1
2005
49
0.010
Why?
Adolescent
2
2020
22451
0.010
Why?
Pattern Recognition, Visual
1
2005
104
0.010
Why?
Photic Stimulation
1
2005
265
0.010
Why?
Sensitivity and Specificity
1
2008
1992
0.010
Why?
Signal Transduction
1
2014
5234
0.010
Why?
Pregnancy
1
2008
7217
0.010
Why?
Child
1
2005
22638
0.000
Why?
Lam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)